BRD4 inhiBition inDuCes homologous
ReComBination DefiCienCy anD it leaDs to synthetiC lethality when assoCiateD with PaRP inhiBitoRs Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are a highly active family of compounds that have changed the scenario in ovarian and human epidermal growth factor receptor 2 (HER2) non-amplified breast cancer management in the recent years. Despite impressive clinical activity, a prolonged treatment with PARPi is frequently associated with acquired resistance to this therapy. The identification of mechanisms and strategies to overcome resistance are crucial. Bromodomain containing 4 (BRD4) is a member of the bromodomain and extraterminal (BET) protein family that facilitates oncogenic transcription. BRD4 is frequently amplified in high-grade serous ovarian cancer (HGSOC) and can be selectively targeted by different compounds.
In a recent publication in Cancer Cell, Sun et al 1 have identified that inhibition of BRD4 (BRD4i) induced homologous recombination (HR) deficiency (HRD) sensitising tumour cells to PARPi, regardless of BRCA1/2, TP53, RAS or BRAF mutation status and reversed mechanisms of resistance to PARPi. BRD4i downregulated the DNA double-strand break (DSB) resection protein, C-terminal binding protein interacting protein (CtIP). CtIP is required to mediate DNA end resection, with loss of CtIP markedly decreasing DNA DSB repair. BRD4 inhibition induced an HRD phenotype in cells through the loss of CtIP expression. Cell damage lead by induction of DNA end resection and HRD after exposure of cells to BRDi and PARPi was dependent on CtIP expression but was not affected by BRCA1 or RAD51 ectopic expression, confirming the critical role of CtIP.
The combination of BRD4i and PARPi was synergistic in most of the 55 tested cell lines. Importantly, this synergism was irrespective of ARID1A, ATM, ATR, BRCA1/2, PI3K, PTEN and TP53 mutation status. Several mechanisms of PARPi resistance have been previously described, including acquired mutations in KRAS, the restoration of BRCA WT expression through UWB1.289 BRCA-1 mutation, the loss of 53BP1 that restore HR function and the loss of PARP-1 that reduces the trapping effect of PARPi. BRD4i has proven in vitro to overcome all these four resistance mechanisms. Finally, in vivo experiments confirmed inhibitory synergistic effect of the combination of BRD4i and PARPi.
These results are encouraging and may have a potential impact in the clinical practice for several reasons. First, this study suggests that BET family and mainly BRD4 plays an important role in the maintenance of HR integrity in the tumour cells. This generates the hypothesis of whether BRD4 or its downregulated target protein CtIP might be a valuable biomarker of HRD and subsequently of PARPi response. Second, it is well known that although not so impressive as in BRCA-mutated patients, PARPi have activity in BRCAwt HGSOC. The potentials shown by BRD4 inhibition to induce a HRD phenotype suggest that increasing sensitivity to PARPi with addition of BRD4 in those patients with HGSOC with no HRD biomarker could be a valuable strategy to be further explored. Third, although these results and the tolerability of the combination need to be tested in the clinic, BRD4i and its synergism with PARPi suggest that the option of treating patients with a PARPi-containing second-line treatment after progression to a previous PARPi could be a reality in a near future.
CaRBoPlatin in BRCa1/2-mutateD anD tRiPle negative BReast CanCeR BRCaness suBgRouPs: the tReating to new taRgets (tnt) tRial Breast cancer is a heterogeneous disease and triple negative (TNBC) subtype is still the less characterised. The BRCAness phenomenon, defined as shared tumour characteristics between sporadic and BRCA-mutated cancers, is supposed to be common in this subgroup. Genomic instability and abnormalities in DNA repair pathways are frequent findings among them. For this reason, platinum compounds are supposed to be more effective than other agents. In a recent issue of Nature Medicine, the TNT trial, which compares the activity of docetaxel versus carboplatin in patients diagnosed with TNBC, has just been published. 2 Among the unselected population, carboplatin was found to be not more active than docetaxel with an overall response rate (ORR) of 31.4 versus 34.0%, respectively. In contrast, among BRCA-mutated tumours, carboplatin, as expected, doubled the ORR of docetaxel (68 vs 33%). Interestingly, such benefit was not confirmed among subjects with BRCA1 methylation, BRCA1 mRNA-low tumours or a high score in a Myriad HRD assay. In these patients, ORR with carboplatin was only 28.6% versus 64.7% for docetaxel. This observation is in contrast with the hypothesis that defects in HR could indicate platinum sensitivity. Moreover, subjects with a high HRD score, unlike carriers of a germ line BRCA1/2 mutation, did not have a better response to carboplatin than to docetaxel (ORR 38.2 vs 40.4%).
The evidence of an overall survival (OS) advantage conferred by carboplatin therapy in carriers of a germ line BRCA1/2 mutation could not be confirmed, but the interpretation of OS could be confounded by the crossover design of the TNT trial. In pretreated patients, clonal pressure due to previous treatment may induce the loss of HRD, making these tumours less sensitive to carboplatin. Additionally, gene expression analysis of basal-like cancers may also influence treatment selection. There is a strong association between BRCA1 mutation and basal-like cancer, and sporadic basal-like breast cancer subtype shows high degrees of chromosomal genomic instability. Despite this, no evidence that basal tumours had a better response to carboplatin compared with docetaxel was found (ORR 32.5 vs 31.0%). Significant interaction between treatment and the basal-like subtype was driven by high docetaxel responses in the non-basal subgroup. In conclusion, patients with advanced TNBC benefit from characterisation of germ line BRCA1/2 mutations, but not from BRCA1 methylation or Myriad HRD analyses, to inform choices on platinum-based chemotherapy.
Some other trials showed improved efficacy with some PARPi, such as olaparib and talazoparib in germ line BRCA1/2-associated metastatic HER2-negative tumours when compared with standard non-platinum chemotherapy. In an accompanying editorial, 3 it is stated that, although TNT data support the continued use of standard-of-care taxanes in non-basal TNBC, carboplatin is clearly an active agent in basal-like TNBC and can be considered as an alternative to docetaxel in these patients. However, in patients with a germ line mutation in BRCA1/2, carboplatin is superior. There may be an important difference in biomarkers between primary and metastatic tumours, and additional research on both platinum salts and PARPi is needed in both settings.
genetiC meChanisms of the immune evasion in ColoReCtal CanCeR: a Potential Role foR wnt inhiBitoRs to ReveRse immune ResistanCe In an extensive cooperative effort from several academic institutions, Grasso et al have recently published in Cancer Discovery, a comprehensive analysis of molecular alterations in a series of 1211 primary colorectal tumours 4 aiming at identifying mutations, pathways and potential oncogenic hotspots. This series includes those samples analysed at the colorectal Cancer Genome Atlas project plus some others coming from the Nurses' Health Study and Health Professionals Follow-up Study. The large number of molecularly characterised specimens makes it possible to understand drivers of immune infiltration. Moreover, it is relevant that they included in this series a high number of highly hypermutated subtypes, including 179 microsatellite instability (MSI)-high cases and 16 POLE mutant cases. It has been observed that some of these hypermutant colon cancers, which are often sensitive to checkpoint inhibitors, have evolved mutations that may confer resistance to immune recognition and therefore to anti-programmed cell death protein 1 (PD1) antibodies. On the other hand, immune resistance in microsatellite stable (MSS) colon cancer may be related to a lower mutational load and poorly defined effector T cell exclusion processes.
In a very elegant work, the authors demonstrate that there are other factors besides mutation load affecting T cell infiltration in both MSI-high and MSS colon cancers. They specifically show that MSI-high frequently undergo immunoediting through complete disruption of both alleles of key genes in the major histocompatibility complex-C antigen presentation pathway and that both MSS and MSI-high tumours have lower T cell infiltration when there are present some molecular events able to upregulate the WNT pathway. WNT signalling genes are well represented as significantly mutated genes in both subtypes of colorectal cancers, while immune-related genes are significantly mutated in MSI-high specifically. In addition, biallelic loss of APC, a gene that upregulates WNT signalling, occurring in 62% of MSS tumours and in 20% of MSI-high cases, is strongly associated with decreased T cell infiltration.
These observations support that MSI-high colorectal tumours display strong evidence of cancer hypermutation of immune-related genes to evolve a means of escape even before treatment with PD1 antibodies. This fact allows those highly mutated tumours to grow and progress unimpeded by immune recognition. On the contrary, MSS colon tumours, harbouring a much lower mutational load have less immunoediting with higher WNT pathway signalling and decreased T cell infiltration.
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